Literature DB >> 35486215

Rare variants in GABRG2 associated with sleep-related hypermotor epilepsy.

Jing Han1, Shui-Bing Liu2, Wen Jiang3, Yong-Li Jiang4, Chang-Geng Song4, Hui-Min Zhou4, Ban Feng5, Jing-Jing Zhao4, Yu Liu4, Yu-Lin Man4.   

Abstract

Sleep-related hypermotor epilepsy (SHE) is a focal epilepsy syndrome. The underlying pathophysiology is presumed to be closely related with disruption of GABAergic neurotransmission, which is mainly medicated by γ-aminobutyric acid type A receptor (GABAAR). Thus, it is reasonable to assume that rare GABAAR variants might contribute to the pathogenesis of SHE. To test this hypothesis, we performed next-generation sequencing in 58 SHE patients and analyzed the functional effects of the identified variants in both neuronal and non-neuronal cells using a combination of electrophysiology recordings, western blot, flow cytometry, and confocal microscopy. In our study, we detected three rare variants (NM_198904.2: c.269C > T, p.T90M; NM_198904.2: c.950C > A, p.T317N and NM_198903.2: c.649C > T, p.Q217X) in GABRG2 (MIM:137,164, encoding GABAAR γ2 subunit) in three unrelated patients. Two of the three rare variants were transmitted unaffected maternally (T90M) or unaffected paternally (Q217X), whereas the T317N variant arose de novo. The mother of proband carrying the T90M variant was unaffected and being mosaicism for this variant. Functional analysis showed that T90M and T317N variants decreased GABA-evoked current amplitudes by diverse mechanisms including impaired surface expression, endoplasmic reticulum retention, and channel gating defects. And Q217X variant reduced synaptic clustering and distribution of GABAAR. While a causal role of these variants cannot be established directly from these results, the functional assessment together with the genetic sequencing suggests that these rare GABRG2 variants may constitute genetic risk factors for SHE. Our study further expands the GABRG2 phenotypic spectrum and supports the view that GABAergic neurotransmission participates in the epileptogenesis of SHE.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  GABAA receptor; GABRG2; Next-generation sequencing; Sleep-related hypermotor epilepsy

Mesh:

Substances:

Year:  2022        PMID: 35486215     DOI: 10.1007/s00415-022-11137-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  42 in total

1.  Two new putative susceptibility loci for ADNFLE.

Authors:  Romina Combi; Luigi Ferini-Strambi; Arianna Montruccoli; Vera Bianchi; Massimo Malcovati; Marco Zucconi; Leda Dalprà; Maria Luisa Tenchini
Journal:  Brain Res Bull       Date:  2005-10-30       Impact factor: 4.077

2.  Nocturnal frontal lobe epilepsy. A clinical and polygraphic overview of 100 consecutive cases.

Authors:  F Provini; G Plazzi; P Tinuper; S Vandi; E Lugaresi; P Montagna
Journal:  Brain       Date:  1999-06       Impact factor: 13.501

3.  Mutations of DEPDC5 cause autosomal dominant focal epilepsies.

Authors:  Saeko Ishida; Fabienne Picard; Gabrielle Rudolf; Eric Noé; Guillaume Achaz; Pierre Thomas; Pierre Genton; Emeline Mundwiller; Markus Wolff; Christian Marescaux; Richard Miles; Michel Baulac; Edouard Hirsch; Eric Leguern; Stéphanie Baulac
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 38.330

4.  A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  O K Steinlein; J C Mulley; P Propping; R H Wallace; H A Phillips; G R Sutherland; I E Scheffer; S F Berkovic
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

5.  Sleep-related hypermotor epilepsy (SHE): Contribution of known genes in 103 patients.

Authors:  Laura Licchetta; Tommaso Pippucci; Sara Baldassari; Raffaella Minardi; Federica Provini; Barbara Mostacci; Giuseppe Plazzi; Paolo Tinuper; Francesca Bisulli
Journal:  Seizure       Date:  2019-11-23       Impact factor: 3.184

6.  Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy.

Authors:  Michael G Ricos; Bree L Hodgson; Tommaso Pippucci; Akzam Saidin; Yeh Sze Ong; Sarah E Heron; Laura Licchetta; Francesca Bisulli; Marta A Bayly; James Hughes; Sara Baldassari; Flavia Palombo; Margherita Santucci; Stefano Meletti; Samuel F Berkovic; Guido Rubboli; Paul Q Thomas; Ingrid E Scheffer; Paolo Tinuper; Joel Geoghegan; Andreas W Schreiber; Leanne M Dibbens
Journal:  Ann Neurol       Date:  2015-12-12       Impact factor: 10.422

Review 7.  Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder.

Authors:  I E Scheffer; K P Bhatia; I Lopes-Cendes; D R Fish; C D Marsden; F Andermann; E Andermann; R Desbiens; F Cendes; J I Manson
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

8.  The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy.

Authors:  M De Fusco; A Becchetti; A Patrignani; G Annesi; A Gambardella; A Quattrone; A Ballabio; E Wanke; G Casari
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

Review 9.  The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Andrea Becchetti; Patrizia Aracri; Simone Meneghini; Simone Brusco; Alida Amadeo
Journal:  Front Physiol       Date:  2015-02-11       Impact factor: 4.566

Review 10.  Definition and diagnostic criteria of sleep-related hypermotor epilepsy.

Authors:  Paolo Tinuper; Francesca Bisulli; J H Cross; Dale Hesdorffer; Philippe Kahane; Lino Nobili; Federica Provini; Ingrid E Scheffer; Laura Tassi; Luca Vignatelli; Claudio Bassetti; Fabio Cirignotta; Christopher Derry; Antonio Gambardella; Renzo Guerrini; Peter Halasz; Laura Licchetta; Mark Mahowald; Raffaele Manni; Carla Marini; Barbara Mostacci; Ilaria Naldi; Liborio Parrino; Fabienne Picard; Maura Pugliatti; Philippe Ryvlin; Federico Vigevano; Marco Zucconi; Samuel Berkovic; Ruth Ottman
Journal:  Neurology       Date:  2016-04-15       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.